Abstract

Provided is a method for detecting donor cfDNA fraction in a sample of a recipient. Also provided is a method for detecting over-represented SNP(s)of donor cfDNA in an identified region.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

A modified hemofiltration method for clearing peripheral α-synuclein aggregates in patients with neurodegenerative diseases is provided, which falls into the field of medicine. Specifically, a ratio S of synuclein dimers in blood is obtained; a blood flow velocity and an exchange membrane area for hemofiltration are determined through clinical trial data or historical literature data; hemofiltration is performed by the determined blood flow velocity and exchange membrane area, a calculation model of the ratio S of different synuclein dimers and an exchange membrane aperture D required for hemofiltration is constructed by linear regression; a clearance rate of synuclein dimers can be estimated by setting hemofiltration parameters with the calculation model. It is found that hemofiltration is beneficial to reducing the level of peripheral α-synuclein aggregates in patients with neurodegenerative diseases. Therefore, the calculation model is constructed, which provides scientific data and a new solution for clinically relieving α-synuclein-related toxicity symptoms.

IPC Classes  ?

• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture

Abstract

An application of a phosphodiesterase inhibitor or a pharmaceutical composition thereof in the preparation of a drug for treating novel coronavirus pneumonia. By means of systematic biology screening and cell-level experiments, it has been verified that zardaverine, pimobendan and crisaborole can inhibit the proliferation of the novel coronavirus to varying degrees at the cell level, zardaverine having the strongest anti-coronavirus effect, followed by pimobendan. All three drugs can be used to prepare a drug for treating novel coronavirus pneumonia.

IPC Classes  ?

• A61K 31/50 - PyridazinesHydrogenated pyridazines
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/69 - Boron compounds
• A61P 31/14 - Antivirals for RNA viruses
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Provided herein are antigen targets determined for 2019-nCoV prevention and treatment and designed corresponding vaccines. In addition, the use of these 4 forms of vaccines for the prevention and treatment of diseases and the preparation of antibodies is provided.

IPC Classes  ?

• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral

Abstract

Disclosed is a drug for treating pulmonary fibrosis in a subject. The drug contains a vector and a polynucleotide encoding a PHB2 protein, wherein the vector contains or carries the polynucleotide encoding a PHB2 protein. Not only can PHB2 have an anti-fibrotic effect with regard to pulmonary fibrosis, same can also inhibit the apoptosis of primary fibroblasts and epithelial cells, inhibit the migration of primary fibroblasts, combat the death of alveolar epithelial cells, and improve the survival rate of cells. These results indicate can treat pulmonary fibrotic diseases by means of targeted PHB2.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Disclosed in the present invention is a negative pressure screen. The negative pressure screen comprises a body weldment, an air inlet device, a purifying device, and negative pressure forming devices; the body weldment comprises a front body frame and a middle body frame, and the front body frame and the middle body frame are integrally connected; the air inlet device is positioned in the middle body frame and is of a plate-shaped frame structure; the purifying device and the negative pressure forming devices are all mounted inside the front body frame, and there are two negative pressure forming devices respectively mounted on the left and right sides of the purifying device. According to the negative pressure screen of the present invention, the structure is compact, consumables are saved, and the cost is reduced; by means of design of the air inlet device, all potentially risky contaminated gas exhaled by a patient can be sucked into the negative pressure screen to be purified and sterilized as much as possible.

IPC Classes  ?

• F24F 3/16 - Air-conditioning systems in which conditioned primary air is supplied from one or more central stations to distributing units in the rooms or spaces where it may receive secondary treatmentApparatus specially designed for such systems characterised by the treatment of the air otherwise than by heating and cooling by purification, e.g. by filteringAir-conditioning systems in which conditioned primary air is supplied from one or more central stations to distributing units in the rooms or spaces where it may receive secondary treatmentApparatus specially designed for such systems characterised by the treatment of the air otherwise than by heating and cooling by sterilisationAir-conditioning systems in which conditioned primary air is supplied from one or more central stations to distributing units in the rooms or spaces where it may receive secondary treatmentApparatus specially designed for such systems characterised by the treatment of the air otherwise than by heating and cooling by ozonisation
• F24F 1/0328 - Self-contained room units for air-conditioning, i.e. with all apparatus for treatment installed in a common casing with means for purifying supplied air
• A61G 7/05 - Parts, details or accessories of beds

Abstract

The invention discloses a use of asarinin in preparation of medicines for treating various coughs. The asarinin is used for preparing medicines for treating various coughs separately or in combination with other medicines. The asarinin can be extracted by an SFE-CO2 method. The asarinin and usable drug carriers or excipients are made into various formulations. And the formulations are granules, tablets, capsules, soft capsules, pills, dripping pills, ointments, syrups, injection, oral liquid, tinctures, sustained-releasing drugs, controlled release drugs or targeting preparations.

IPC Classes  ?

• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• C07D 493/04 - Ortho-condensed systems
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 36/264 - Aristolochia (Dutchman's pipe)

Abstract

Asarum polysaccharide extract has the effects of reducing the cough sensitivity and suppressing the airway inflammation for the first time, has excellent preventive and therapeutic effects on various types of coughs, and can be used for preparing the medicines for preventing and treating cough-related diseases.

IPC Classes  ?

• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 36/268 - Asarum (wild ginger)

Abstract

The invention discloses a percutaneous puncture and dilation visible irrigation-suction system and a method of using the same. The system comprises a main tube, which is contiguous with the sheath tube and has an end for an endoscope insertion. The sheath tube comprises an inner sheath and an outer sheath joined together in a sleeve type. There is a space between inner and outer sheath. The inner sheath is connected to main tube, together building a channel via which the endoscope is inserted and withdrawn. The sheath tube is connected to main tube after completing puncture and dilation, then endoscope system is introduced for observation and operation. The present invention provides a percutaneous puncture and dilation visible irrigation-suction system and a method of using the same, with a continuous controllable visible negative pressure aspirator, achieving high irrigation and powerful suction efficiency, as well as clear endoscopic view.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/313 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes
• A61B 1/015 - Control of fluid supply or evacuation
• A61B 17/34 - TrocarsPuncturing needles
• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with cooling or rinsing arrangements
• A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements

Abstract

The present invention relates to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for treating coughing, and more specifically to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for preventing and relieving coughing and eliminating airway inflammation. Experiments demonstrate that the Fructus schisandrae total polysaccharides can remarkably reduce the coughing times of a guinea pig with increased cough sensitivity induced by cigarette smoke and an acute cough guinea pig induced by citric acid smoke, prolong the latent period of cough, and significantly reduce the airway inflammation of the guinea pig with increased cough susceptibility induced by cigarette smoke, so that the Fructus schisandrae total polysaccharides can be used for preparing drugs for preventing cough, relieving cough and eliminating airway inflammation.

IPC Classes  ?

• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 36/79 - Schisandraceae (Schisandra family)
• A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
• A23P 10/00 - Shaping or working of foodstuffs characterised by the products

Abstract

Provided are a method for extracting high-purity asarinin and use thereof, which belong to the field of natural medicines. The method comprises: putting coarse asarum powder in a supercritical CO2 extraction device; under the conditions that an extraction kettle has a pressure of 30-40 Mpa and a temperature of 45-70℃, separating kettles I and II have a pressure of 5-10 Mpa and a temperature of 30-50℃ and the flow rate of CO2 is 35-60 L/h, extracting for 60 to 240 minutes to obtain asarum total volatile oil; standing the asarum total volatile oil for 24-72 hours at a low temperature, and filtering under reduced pressure to obtain an asarinin coarse product; re-crystallizing the asarinin coarse product in absolute ethanol twice to obtain an asarinin pure product. In addition, it is found for the first time that asarinin has a good cough-relieving activity and thus can be used in preparing medicines for treating various types of coughs. Firstly disclosed is a brand-new preparation process for extracting asarinin by a supercritical CO2 extraction method, and this method has the advantages of simple process, no solvent residue, high product purity, etc.

IPC Classes  ?

• A61K 36/264 - Aristolochia (Dutchman's pipe)
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• C07D 493/04 - Ortho-condensed systems
• A61P 11/14 - Antitussive agents

Abstract

Disclosed are a schisandra extract and a preparation method thereof, and a use in the preparation of drugs or health care products for treating coughs and alleviating airway inflammations. The preparation method comprises the steps of using schisandra as a raw material, carrying out reflux extraction three times by using ethanol, mixing the extracting solutions, and filtering after standing to obtain an extract A, wherein each extraction operation lasts for 1-3 h; decocting dregs in water three times, mixing the extracting solutions, and filtering after standing to obtain an extract B, wherein each decoction operation lasts for 1-3 h; and mixing the extracts A and B, and carrying out vacuum drying to obtain the schisandra extract.

IPC Classes  ?

• A61K 36/79 - Schisandraceae (Schisandra family)
• A61K 36/57 - Magnoliaceae (Magnolia family)
• A23L 1/29 - Modifying nutritive qualities of foods; Dietetic products ( A23L 1/09 takes precedence;dietetic salt substitutes A23L 1/22)
• A61P 11/14 - Antitussive agents
• A61P 11/10 - Expectorants
• A61K 131/00 - Containing or obtained from seeds, nuts, fruits or grains

Abstract

An application of Fructus schisandrae total polysaccharides in the preparation of medicine or nutraceuticals used for treating coughing, and a pharmaceutical or nutraceutical composition containing Fructus schisandrae total polysaccharides. Experiments demonstrate that Fructus schisandrae total polysaccharides can be used for preparing antitussive and cough relief medicine and medicine to eliminate inflammation of the airways.

IPC Classes  ?

• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61P 11/14 - Antitussive agents
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23L 1/09 - containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin (A23L 1/76, A23L 1/236 take precedence);;

Abstract

The present invention relates to a novel application of fructus schisandrea total lignans in the preparation of medicine or nutraceuticals used for treating coughing, specifically to a novel application in the preparation of antitussive and cough relief medicine or nutraceuticals and medicine or nutraceuticals to eliminate inflammation of the airways. Experiments demonstrate that fructus schisandrea total lignans can significantly reduce the frequency of cough hypersensitivity induced by cigarette smoke and acute coughing induced by citric acid fumes in guinea pigs and prolong the period of cough latency, and can significantly alleviate airway inflammation of guinea pigs having cough hypersensitivity induced by cigarette smoke, demonstrating that fructus schisandrea total lignans can be used for preparing antitussive and cough relief medicine and medicine to eliminate inflammation of the airways.

IPC Classes  ?

• A61K 36/57 - Magnoliaceae (Magnolia family)
• A61K 36/79 - Schisandraceae (Schisandra family)
• A61P 11/14 - Antitussive agents
• A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Disclosed are an asarum total polysaccharides extract having antitussive activity and an extraction method thereof and a use for preparing a medicant for prevention and treatment of coughing. The asarum is extracted with a polar solvent under hot reflux, concentrated under reduced pressure, dried and then dissolved in water, and precipitated by adding ethanol. The precipitate is washed to obtain the asarum total polysaccharides extract. The polysaccharide percent content of the asarum total polysaccharides extract is 60wt%-80wt%. The asarum total polysaccharides extract has the effects of suppressing coughs and prolonging the latent period of coughs, and also has the effects of reducing the sensitivity of coughs and inhibiting airway inflammation, and can be used for preparing a medicament for prevention and treatment of diseases related to coughing.

IPC Classes  ?

• A61K 36/264 - Aristolochia (Dutchman's pipe)
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61P 11/14 - Antitussive agents

Abstract

Provided are a segmentation method and device based on an image of radionuclide imaging, including: determining a potential target region from an image of radionuclide imaging using a standardized value of pixels in the image of radionuclide imaging and an average standardized value and a standard deviation of pixels in a non-target region, and according to the boundary pixels and pixels within a boundary of the potential target region, and the average standardized value of the pixels of the non-target region, finally determining the boundary of a target of interest. The method or device needs to receive a non-target region selected by a user only when calculating an average standardized value and a standard deviation of pixels in the non-target region, thus significantly reducing manual intervention of a link, so as to avoid the subjectivity of segmentation results and improve the certainty of the segmentation results.

IPC Classes  ?

• G06T 7/00 - Image analysis